Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

QUOTED. 7 October 2019. Doug Stearn.

Executive Summary

Once upon a time, the US FDA's largest challenge around recalls communication was getting the word out about potentially dangerous products. But now a bigger risk is that recall notifications will be missed in a daily flood of communications, the agency's Doug Stearn says. Check out his comment here.

“People overlook [recalls] information because there’s too much of it.” – Doug Stearn, deputy director for regulatory affairs, US FDA’s Center for Food Safety and Applied Nutrition

Click here for a free trial of Medtech Insight

 

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT125726

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel